Relay Therapeutics Inc
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs apply
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Find out what a historical investment in Relay Therapeutics Inc would be worth today using our RLAY stock calculator.
$617.20M
-
0.00%
1.33M
$3.74
$3.56
$3.60
$10.72
$1.78
Ready to start your investing journey with Stake?
Open an accountRLAY FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in RLAY
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in RLAY
on Stake
Buy RLAY from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of RLAY from only US$10 with fractional shares
